KeyBanc raised the firm’s price target on UnitedHealth (UNH) to $400 from $350 and keeps an Overweight rating on the shares. The firm’s credit card data and checks suggest utilization remains elevated yet stable through Q3, with some potential for a very slight sequential moderation. For Hospitals and Post Acute, KeyBanc expects beats/raises with Q3, supported by solid patient volumes, favorable labor dynamics, and continued upside from SDPs. Additionally, for Hospitals, the firm expects 2026 EBITDA will move higher into year-end, aided by a deal on HIX subsidies, even more SDPs, and the Rural Health Program. For MCOs and VBC, a stable utilization environment is likely good enough, as guidance assumptions lean conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth’s Earnings Outlook: Balancing Potential Upside with Uncertainty
- UnitedHealth price target raised to $400 from $267 at Wells Fargo
- UNH vs. LLY vs. HIMS: Which Healthcare Stock Is the Best Pick, According to Analysts?
- UnitedHealth Group Stock Forecast: AI Analyst Backs Bullish Case for UNH
- Looking for Exposure to UnitedHealth Stock (UNH)? Here’s How to Buy Without the Risk